Episode 246: ASCO 2023 - EV Pembrolizumab and Erdafitinib Cetrelimab in First-line UC

Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023, including the EV-103 trial on enfortumab vedotin alone and in combination with other therapies for the treatment of urothelial carcinoma.
Dr. Gupta is director of the Genitourinary Medical Oncology unit at Cleveland Clinic’s Taussig Cancer Institute, and is co-leader of the Genitourinary Oncology Program at Cleveland Clinic.